Teduglutide

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 42591359 · DOI 10.3389/fped.2026.1898958

Background: Short bowel syndrome (SBS) is the leading cause of chronic intestinal failure and is frequently associated with long-term dependence on parenteral nutrition (PN) and intravenous fluids. Teduglutide, a glucagon-like peptide-2 (GLP-2) analogue, promotes intestinal adaptation and has been demonstrated to reduce parenteral support requirements. However, real-world data from the Greek population are scarce. Methods: We conducted a non-interventional, multicenter, retrospective cohort study across 5 centers in Greece, including adult patients with SBS receiving teduglutide therapy. Demographic and clinical characteristics, parenteral nutrition and intravenous fluid requirements, body mass index (BMI), laboratory parameters, and adverse events were recorded at baseline and during follow-up at weeks 4, 12, 26, and 52. Results: Eight adult patients with SBS were included (75% female),…

open access ↗ · PMID 41827448 · DOI 10.3390/jcm15052033

AbstractPaediatric short bowel syndrome (SBS) with chronic intestinal failure (IF) is a rare, complex and potentially life-threatening condition. The main causes in children are necrotizing enterocolitis, volvulus, congenital malformations, and other enteropathies. The resulting reduced intestinal absorption capacity often requires parenteral nutrition (PN), which is associated with complications such as catheter infections, liver disease, and thrombosis, as well as significant limitations in quality of life. The goal of multidisciplinary treatment is to achieve enteral autonomy, prevent complications, and improve quality of life. With the introduction of the glucagon-like peptide-2 analogue (GLP-2-analogue) teduglutide, an additional therapeutic option is available that can improve fluid and nutrient absorption and reduce the need for parenteral support, up to partial or complete weanin…

open access ↗ · PMID 41672430 · DOI 10.1055/a-2757-3525

Teduglutide is a glucagon-like peptide 2 (GLP-2) analogue that was approved by the United States Food and Drug Administration for the treatment of pediatric (>1 year) intestinal failure due to short bowel syndrome in 2019. GLP-2 analogues promote rapid intestinal adaptation, increasing the absorptive capacity of residual intestine after surgical resection to aid the achievement of enteral autonomy or reduce parenteral nutrition requirements. Despite relatively few reported side effects, there is a theoretical risk of proliferative complications. Here we present an intriguing case of a pediatric patient found to have a decade-long retained, discontinuous segment of colon from a surgical procedure performed in infancy, which became clinically significant after a period of treatment with teduglutide.

open access ↗ · PMID 41245050 · DOI 10.1002/jpr3.70049

Background/Objectives: Short bowel syndrome (SBS) is the leading cause of pediatric intestinal failure. Plasma citrulline is considered a marker indicating an enterocyte volume and may help evaluate the response to teduglutide; however, this interpretation may vary depending on the remnant bowel anatomy. Methods: We conducted a retrospective case series of four pediatric patients with SBS (aged Results: This study included two males and two females. All patients showed an increase in plasma citrulline levels and a reduction in the requirement for parenteral nutrition (PN) after 12 months of teduglutide treatment. In SBS type 2 (jejunocolic anastomosis), citrulline levels increased by 114% and 52%, with PN reduction rates of 100% and 30%, respectively. In SBS type 3 (jejunoileal anastomosis), citrulline levels increased by 13.6% and 34%, with PN reductions of 33% and 73%, respectively. Co…

open access ↗ · PMID 40868429 · DOI 10.3390/children12080977

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 42622692 · DOI 10.1007/s00383-026-06474-8

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 42410547 · DOI 10.1186/s12887-026-07283-7

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 42385596 · DOI 10.1016/j.talanta.2026.130223